Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?

The gastrointestinal tract secretes gut hormones in response to food consumption, and some of these stimulate insulin secretion. Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone released from the lower digestive tract that stimulates insulin secretion, suppresses glucagon secretion, an...

Full description

Bibliographic Details
Main Authors:	Hwi Seung Kim, Chang Hee Jung
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	International Journal of Molecular Sciences
Subjects:	semaglutide GLP-1 receptor type 2 diabetes obesity
Online Access:	https://www.mdpi.com/1422-0067/22/18/9936

Similar Items

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
by: Alorfi NM, et al.
Published: (2022-08-01)

Semaglutide for the treatment of obesity
by: Rafał Oleszczuk, et al.
Published: (2022-01-01)

Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China
by: Zhen Feng, et al.
Published: (2023-08-01)

Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process
by: Marcin Hachuła, et al.
Published: (2024-02-01)

Glycemic treatment effect of oral semaglutide plus other antidiabetic medications: An Indian experience
by: Manoj Chawla, et al.
Published: (2022-01-01)

Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov
by: Alorfi NM, et al.
Published: (2023-07-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

Anti-inflammatory benefits of semaglutide: State of the art
by: Habib Yaribeygi, et al.
Published: (2024-06-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
by: Yoshinori Ozeki, et al.
Published: (2022-09-01)

Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
by: Evgenia Koureta, et al.
Published: (2024-02-01)

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
by: Chao AM, et al.
Published: (2022-12-01)

Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study
by: Marcin Hachuła, et al.
Published: (2023-08-01)

Possibilities of a new glucagon-like peptide-1 receptor agonist Semaglutide in improving left ventricular diastolic function in a patient with arterial hypertension and type 2 diabetes mellitu
by: Makka R. Azimova, et al.
Published: (2021-12-01)

Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
by: Han Ah Lee, et al.
Published: (2023-05-01)

Advances in GLP-1 treatment: focus on oral semaglutide
by: Freddy G. Eliaschewitz, et al.
Published: (2021-09-01)

Clinical potential of treatment with semaglutide in type 2 diabetes patients
by: Michael E Røder
Published: (2019-12-01)

A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
by: Selvarajan R, et al.
Published: (2023-06-01)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2021-01-01)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022-10-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

Editorial: Incretin agonists in the treatment of obesity
by: Xiaodong Sun, et al.
Published: (2023-08-01)

The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus
by: Ahmad A Algarni, et al.
Published: (2024-01-01)

Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity.
by: Kamil Pondel, et al.
Published: (2022-08-01)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
by: Baptist Gallwitz, et al.
Published: (2021-06-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023-02-01)

Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study
by: Angham Almutair, et al.
Published: (2024-03-01)

Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01)

Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice
by: Yermek Rakhat, et al.
Published: (2023-08-01)

Corrigendum: Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-11-01)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
by: Han Na Jung, et al.
Published: (2022-03-01)

The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis
by: Yousef Alhindi, et al.
Published: (2022-08-01)

Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease
by: Manuel Soto-Catalán, et al.
Published: (2024-03-01)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
by: Juris J. Meier
Published: (2021-06-01)

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention
by: Xiong C, et al.
Published: (2024-02-01)

Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
by: Riccardo Candido, et al.
Published: (2023-09-01)

Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes
by: Xin Zhang, et al.
Published: (2021-07-01)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
by: Mihaela-Simona Popoviciu, et al.
Published: (2023-06-01)

Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients
by: Deene Mohandas, et al.
Published: (2023-02-01)